Ana Aparicio

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Platinum-based chemotherapy for variant castrate-resistant prostate cancer
    Ana M Aparicio
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 3721, USA
    Clin Cancer Res 19:3621-30. 2013
  2. pmc Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data
    Ivan P Gorlov
    Department of Genitourinary Medical Oncology, The University of Texas M, Anderson Cancer Center, Houston, TX, USA
    BMC Med Genomics 2:48. 2009
  3. pmc Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles
    Ana Aparicio
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Prostate 71:846-56. 2011
  4. pmc LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors
    Ana Aparicio
    Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Epigenetics 4:176-84. 2009
  5. doi request reprint Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
  6. doi request reprint Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer
    Christopher J Logothetis
    Departments of 1Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Discov 3:849-61. 2013
  7. doi request reprint Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department ofGenitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4076-81. 2009
  8. ncbi request reprint Understanding the lethal variant of prostate cancer: power of examining extremes
    Ana Aparicio
    Department of Genitourinary Medical Oncology, David H Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Discov 1:466-8. 2011
  9. doi request reprint TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate
    Charles C Guo
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Hum Pathol 42:11-7. 2011
  10. ncbi request reprint Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:2872-80. 2009

Detail Information

Publications13

  1. pmc Platinum-based chemotherapy for variant castrate-resistant prostate cancer
    Ana M Aparicio
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 3721, USA
    Clin Cancer Res 19:3621-30. 2013
    ....
  2. pmc Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data
    Ivan P Gorlov
    Department of Genitourinary Medical Oncology, The University of Texas M, Anderson Cancer Center, Houston, TX, USA
    BMC Med Genomics 2:48. 2009
    ..Suppression of integrin expression driven by integrin-mediated cell death leads to increased cell proliferation and motility and increased tumor malignancy...
  3. pmc Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles
    Ana Aparicio
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Prostate 71:846-56. 2011
    ..Large-cell neuroendocrine carcinoma (LCNEC) is a much rarer variant that behaves similarly to SCC. The biological mechanisms that drive these disease variants are poorly understood...
  4. pmc LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors
    Ana Aparicio
    Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Epigenetics 4:176-84. 2009
    ..Ongoing studies will determine whether changes in LINE-1 methylation in plasma DNA occur as a result of treatment with DNA methylation inhibitors and parallel changes in tumor tissue DNA...
  5. doi request reprint Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
    ..The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC)...
  6. doi request reprint Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer
    Christopher J Logothetis
    Departments of 1Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Discov 3:849-61. 2013
    ..We use this model to discuss how integrating clinical and basic understanding of prostate cancer will lead to better implementation of molecularly targeted therapeutics and improve patient survival. ..
  7. doi request reprint Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department ofGenitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4076-81. 2009
    ....
  8. ncbi request reprint Understanding the lethal variant of prostate cancer: power of examining extremes
    Ana Aparicio
    Department of Genitourinary Medical Oncology, David H Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Discov 1:466-8. 2011
    ....
  9. doi request reprint TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate
    Charles C Guo
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Hum Pathol 42:11-7. 2011
    ..The high prevalence of the TMPRSS2-ERG gene fusion in prostatic small cell carcinoma as well as adenocarcinoma implies that small cell carcinoma may share a common pathogenic pathway with adenocarcinoma in the prostate...
  10. ncbi request reprint Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:2872-80. 2009
    ..The authors of this report investigated the clinical outcome of patients who had prostate ductal adenocarcinoma after primary radical prostatectomy or radiotherapy...
  11. pmc A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma
    Nizar M Tannir
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Eur Urol 62:1013-9. 2012
    ..Sunitinib is a standard-of-care treatment in advanced clear cell renal cell carcinoma (ccRCC). Retrospective and expanded access data suggest sunitinib has activity in advanced non-clear cell renal cell carcinoma (nccRCC)...
  12. doi request reprint Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer
    Kanishka Sircar
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Pathol 180:895-903. 2012
    ..Together, our results suggest that ASNS is up-regulated in cases of CRPC and that depletion of asparagine using ASNS inhibitors will be a novel strategy for targeting CRPC cells...
  13. pmc Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer
    Ana Aparicio
    Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Urol 8:562-8. 2011
    ..Here, the current state of knowledge regarding the implications of RB loss for prostate cancer progression will be reviewed, and potential opportunities for developing RB as a metric to predict therapeutic response will be considered...